Scarica l'app Stockscreener
1.53
1.22%
-0.03
Precedente Chiudi:
$1.56
Aprire:
$1.58
Volume 24 ore:
1.15M
Relative Volume:
3.73
Capitalizzazione di mercato:
$59.26M
Reddito:
-
Utile/perdita netta:
$-37.75M
Rapporto P/E:
-0.4608
EPS:
-3.32
Flusso di cassa netto:
$-30.91M
1 W Prestazione:
-23.33%
1M Prestazione:
-26.97%
6M Prestazione:
-52.58%
1 anno Prestazione:
-27.99%
Intervallo 1D:
$1.385
$1.58
Intervallo di 1 settimana:
$1.385
$2.035
Portata 52W:
$1.385
$4.45
Cellectar Biosciences Inc Stock (CLRB) Company Profile
Nome
Cellectar Biosciences Inc
Settore
Industria
Telefono
(608) 441-8120
Indirizzo
100 CAMPUS DRIVE, FLORHAM PARK, NJ
Confronta CLRB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| CLRB | 1.535 | 59.26M | 0 | -37.75M | -30.91M | -3.32 |
| VRTX | 449.14 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 748.83 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 587.39 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.01 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 106.99 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Cellectar Biosciences Inc Stock (CLRB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2020-07-01 | Iniziato | Oppenheimer | Outperform |
| 2020-01-21 | Ripresa | ROTH Capital | Buy |
| 2019-09-13 | Iniziato | ROTH Capital | Buy |
| 2016-12-21 | Iniziato | Ladenburg Thalmann | Buy |
Cellectar Biosciences Inc Borsa (CLRB) Ultime notizie
Oppenheimer Lowers Cellectar Biosciences (NASDAQ:CLRB) Price Target to $12.00 - Defense World
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q3 2024 Earnings Call Transcript - Insider Monkey
Cellectar Signs Critical Radioisotope Supply Deal for Cancer Drug Development | CLRB Stock News - StockTitan
Roth Capital Brokers Decrease Earnings Estimates for CLRB - MarketBeat
Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides Corporate Update - Defense World
Equities Analysts Offer Predictions for CLRB Q1 Earnings - Defense World
Q1 Earnings Estimate for CLRB Issued By Roth Capital - MarketBeat
Oppenheimer cuts Cellectar Biosciences stock target, outperform on Q3 financials - Investing.com UK
Oppenheimer Has Lowered Expectations for Cellectar Biosciences (NASDAQ:CLRB) Stock Price - MarketBeat
Cellectar Biosciences Reports Q3 2024 Financial Results - TipRanks
Cellectar Biosciences Inc reports results for the quarter ended September 30Earnings Summary - XM
Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update - GlobeNewswire
Cellectar Biosci stock hits 52-week low at $1.82 By Investing.com - Investing.com Canada
Cellectar Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Cellectar corrects accounting firm consent in SEC filing - Investing.com
Cellectar corrects accounting firm consent in SEC filing By Investing.com - Investing.com Australia
Earnings call: Cellectar Biosciences delays NDA submission for iopofosine I 131 - Investing.com Canada
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Short Interest Down 6.1% in October - MarketBeat
Cellectar Biosciences Inc (CLRB) Quarterly 10-Q Report - Quartzy
Cellectar Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits - Quantisnow
Cellectar Reports Positive Phase 2 Results, Secures $19.4M in Warrant Exercises | CLRB Stock News - StockTitan
SEC Form 10-Q filed by Cellectar Biosciences Inc. - Quantisnow
Cellectar Biosciences (CLRB) Scheduled to Post Earnings on Monday - Defense World
Cellectar Biosciences Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits - Quantisnow
ADAR1 Capital Management, LLC Expands Stake in Cellectar Bioscie - GuruFocus.com
Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225 - GlobeNewswire
Cellectar Partners With NorthStar For Ac-225 Supply - Contract Pharma
Cellectar secures Ac-225 supply for cancer drug development - Investing.com
Cellectar Secures 10-Year Supply of Rare Cancer Treatment Isotope for Clinical Trials | CLRB Stock News - StockTitan
Cellectar Biosciences and SpectronRx Partner to Manufacture - GlobeNewswire
Cellectar Biosciences (CLRB) Scheduled to Post Quarterly Earnings on Monday - MarketBeat
Cellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cancer - The Manila Times
Cellectar Signs Key Manufacturing Deal for Breakthrough Cancer Therapy Ahead of 2025 Launch | CLRB Stock News - StockTitan
CLRB (Cellectar Biosciences) 3-Year EBITDA Growth Rate : 25.40% (As of Jun. 2024) - GuruFocus.com
Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Monday, November 18, 2024 - The Manila Times
Cellectar Biosciences to Report Third Quarter Financial - GlobeNewswire
Cellectar Selected to Present New Data from Phase 2 CLOVER-WaM Study in Oral Session at ASH 2024 - GlobeNewswire
Cellectar's Breakthrough WM Cancer Drug Data Set for Major ASH 2024 Presentation | CLRB Stock News - StockTitan
Rosalind Advisors Inc. Increases Stake in Cellectar Biosciences, Inc. (NASDAQ:CLRB) - MarketBeat
S&P 500 Index (INX) QuotePress Release - The Globe and Mail
Cellectar Biosciences Announces Compliance Regarding Filing of Form 10-Q - GlobeNewswire
Sequoia Financial Advisors LLC Purchases New Stake in Cellectar Biosciences, Inc. (NASDAQ:CLRB) - Defense World
Current and Future Analysis of Neuroblastoma Therapeutic - openPR
Waldenstrom Macroglobulinemia Market to Show Remarkable - openPR
Cellectar Biosciences (NASDAQ:CLRB) Stock Price Crosses Above 50-Day Moving AverageHere's What Happened - MarketBeat
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Sees Large Increase in Short Interest - MarketBeat
Bone Cancer Drugs Market Next-Generation Dynamic Growth - openPR
Cellectar Biosciences (NASDAQ:CLRB) Receives Outperform Rating from Oppenheimer - Defense World
Cellectar Biosciences (NASDAQ:CLRB) Given Outperform Rating at Oppenheimer - MarketBeat
Oppenheimer maintains Outperform rating on Cellectar Biosciences By Investing.com - Investing.com Canada
Cellectar Biosciences (NASDAQ:CLRB) Shares Cross Above Fifty Day Moving Average – Here’s Why - Defense World
Cellectar Biosciences Inc Azioni (CLRB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.80%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):